
THERE'S A LOT TO CONSIDER
WHEN PRESCRIBING AN
EXTENDED-RELEASE OPIOID
Abuse-deterrent properties do not prevent or reduce the risk of addiction.1
Abuse of OxyContin by the intravenous, intranasal, and oral routes is still possible.
Reference: 1. US Food and Drug Administration. Remarks delivered before FDA's scientific meeting on opioids. July 10, 2017. https://www.fda.gov/NewsEvents/Speeches/ucm566189.htm. Accessed February 21, 2018.